Linked Life Data

16680834

Source:http://linkedlifedata.com/resource/pubmed/id/16680834

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2006-5-8
pubmed:abstractText
Bone metastases, the most common metastatic manifestation of many cancers, including breast cancer and prostate cancer, contribute significantly to the pain and disability often associated with later stages of malignant disease. Although bisphosphonates have demonstrated efficacy in the treatment of metastatic bone disease (MBD), identifying patients most likely to develop bone metastases (and thus to benefit from treatment) is a challenge. In recent years, advances in understanding the pathophysiologic underpinnings of bone metastases have led to the discovery of several potential markers for dysregulation of bone coupling. Trials have been conducted to validate these biochemical markers and to explore their possible role in measuring efficacy of bisphosphonate treatment and of other metastatic bone therapies. In no area is this research more important than in the management of breast cancer. Although the value of these bone turnover markers is still unclear, and further research is necessary, results from these recent trials indicate some correlation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0305-7372
pubmed:author
pubmed:issnType
Print
pubmed:volume
32 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
20-2
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Biochemical bone markers in breast cancer.
pubmed:affiliation
Division of Oncology, Room C6830, Hershey Medical Center, Hershey, PA 17033, USA. alipton@psu.edu
pubmed:publicationType
Journal Article, Review